Thiazolides as novel antiviral agents. 1. Inhibition of hepatitis B virus replicationStachulski, A.V., Pidathala, C., Row, E.C., Sharma, R., Berry, N.G., Iqbal, M., Bentley, J., Allman, S.A., Edwards, G., Helm, A., Hellier, J., Korba, B.E., Semple, J.E. and Rossignol, J.-F. (2011) Thiazolides as novel antiviral agents. 1. Inhibition of hepatitis B virus replication. Journal of Medicinal Chemistry, 54 (12). pp. 4119-4132. ISSN 0022-2623 Full text not archived in this repository. It is advisable to refer to the publisher's version if you intend to cite from this work. See Guidance on citing. To link to this item DOI: 10.1021/jm200153p Abstract/SummaryWe report the syntheses and activities of a wide range of thiazolides [viz., 2-hydroxyaroyl-N-(thiazol-2-yl)amides] against hepatitis B virus replication, with QSAR analysis of our results. The prototypical thiazolide, nitazoxanide [2-hydroxybenzoyl-N-(5-nitrothiazol-2-yl)amide, NTZ] 1 is a broad spectrum antiinfective agent effective against anaerobic bacteria, viruses, and parasites. By contrast, 2-hydroxybenzoyl-N-(5-chlorothiazol-2-yl)amide 3 is a novel, potent, and selective inhibitor of hepatitis B replication (EC50 = 0.33 μm) but is inactive against anaerobes. Several 4′- and 5′-substituted thiazolides show good activity against HBV; by contrast, some related salicyloylanilides show a narrower spectrum of activity. The ADME properties of 3 are similar to 1; viz., the O-acetate is an effective prodrug, and the O-aryl glucuronide is a major metabolite. The QSAR study shows a good correlation of observed EC90 for intracellular virions with thiazolide structural parameters. Finally we discuss the mechanism of action of thiazolides in relation to the present results.
Altmetric Deposit Details University Staff: Request a correction | Centaur Editors: Update this record |
Lists
Lists
